173 related articles for article (PubMed ID: 3026001)
21. Ampicillin/sulbactam versus metronidazole-gentamicin in the treatment of soft tissue pelvic infections.
Crombleholme WR; Ohm-Smith M; Robbie MO; DeKay V; Sweet RL
Am J Obstet Gynecol; 1987 Feb; 156(2):507-12. PubMed ID: 3030109
[TBL] [Abstract][Full Text] [Related]
22. [Antimicrobial activities of sulbactam/ampicillin against clinically isolated microbial strains].
Deguchi K; Yokota N; Koguchi M; Suzuki Y; Fukayama S; Ishihara R; Oda S; Tanaka S; Nakane Y; Fukumoto T
Jpn J Antibiot; 1995 Apr; 48(4):529-47. PubMed ID: 7783316
[TBL] [Abstract][Full Text] [Related]
23. Susceptibility of Haemophilus ducreyi to ampicillin and sulbactam in vitro.
Jones BM; Hafiz S; Duerden BI
Antimicrob Agents Chemother; 1986 Jun; 29(6):1110-2. PubMed ID: 3015016
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of aminopenicillins combined with sulbactam, clavulanic acid, or amdinocillin against bacteria isolated from patients with complicated urinary tract infections.
Naber KG; Wittenberger R
Rev Infect Dis; 1986; 8 Suppl 5():S604-8. PubMed ID: 3026011
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of sulbactam/ampicillin and ampicillin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
Fabbri A; Tacchella A; Belli ML; Losurdo G
Chemioterapia; 1988 Oct; 7(5):306-8. PubMed ID: 3224398
[TBL] [Abstract][Full Text] [Related]
26. [Comparative in vitro activity of ampicillin, cefoperazone, their combinations with sulbactam and other antibiotics with respect to staphylococci and pneumococci].
Sidorenko SV; Rezvan SP; Speranskaia ON; Tikhonova As; Navashin SM; Ansolis LE; Tsvigun EA; Kuleshov SE; Budanov SV
Antibiot Khimioter; 1995 Mar; 40(3):22-7. PubMed ID: 7575010
[TBL] [Abstract][Full Text] [Related]
27. In vitro evaluations of aminopenicillin/beta-lactamase inhibitor combinations.
Jones RN
Drugs; 1988; 35 Suppl 7():17-26. PubMed ID: 3265377
[TBL] [Abstract][Full Text] [Related]
28. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin.
Schmalreck AF; Wildfeuer A
Arzneimittelforschung; 1990 Oct; 40(10):1145-55. PubMed ID: 2291754
[TBL] [Abstract][Full Text] [Related]
30. [Sulbactam and clavulanic acid: studies of enzyme kinetics and synergism with ampicillin and mezlocillin].
Cullmann W; Binder S; Stieglitz M
Immun Infekt; 1987 May; 15(3):103-9. PubMed ID: 3038733
[TBL] [Abstract][Full Text] [Related]
31. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
Zhao C; Xie W; Zhang W; Ye Z; Wu H
Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
[TBL] [Abstract][Full Text] [Related]
32. Intravenous sulbactam/ampicillin in the treatment of pediatric infections.
Lee CY; Lin TY; Chu ML; Lee MJ; Hsu CY; Huang LM; Chen CM
Diagn Microbiol Infect Dis; 1989; 12(4 Suppl):179S-183S. PubMed ID: 2686918
[TBL] [Abstract][Full Text] [Related]
33. Antibacterial activity of the sulbactam-ampicillin combination.
Sessarego FV; Botta GA; Pesce A; Schito GC
J Chemother; 1989 Dec; 1(6):384-7. PubMed ID: 2614505
[TBL] [Abstract][Full Text] [Related]
34. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
Housman ST; Hagihara M; Nicolau DP; Kuti JL
J Antimicrob Chemother; 2013 Oct; 68(10):2296-304. PubMed ID: 23710070
[TBL] [Abstract][Full Text] [Related]
35. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
Gatermann S; Marre R
Infection; 1991; 19(2):106-9. PubMed ID: 1646771
[TBL] [Abstract][Full Text] [Related]
36. An open, comparative study of sulbactam plus ampicillin vs. cefotaxime as initial therapy for serious soft tissue and bone and joint infections.
Löffler L; Bauernfeind A; Keyl W; Hoffstedt B; Piergies A; Lenz W
Rev Infect Dis; 1986; 8 Suppl 5():S593-8. PubMed ID: 3026009
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of beta-lactamase-induced resistance in soft-tissue infections.
Nichols RL; Smith JW; Adinolfi MF; Galli R; Vivoda LM
Arch Surg; 1985 Jan; 120(1):36-42. PubMed ID: 2981523
[TBL] [Abstract][Full Text] [Related]
38. Sulbactam/ampicillin in paediatric infections.
Dajani AS
Drugs; 1988; 35 Suppl 7():35-8. PubMed ID: 3065053
[TBL] [Abstract][Full Text] [Related]
39. Treatment of ampicillin-resistant acute otitis media in the chinchilla.
Reilly JS; Doyle WJ; Cantekin EI; Supance JS; Kim HK; Rohn DD; Bluestone CD
Arch Otolaryngol; 1983 Aug; 109(8):533-5. PubMed ID: 6307238
[TBL] [Abstract][Full Text] [Related]
40. Ampicillin/sulbactam (Unasyn).
Med Lett Drugs Ther; 1987 Aug; 29(747):79-81. PubMed ID: 3039328
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
